Among the many types of cancer, Squamous Cell Carcinoma of the Lung is one of the most serious and can be fatal if not treated properly. There are several treatment options available, such as radiation therapy, chemotherapy, and surgery. Some treatments may be effective for some patients, while others are ineffective.
Depending on the stage of the disease, treatment options for squamous cell carcinoma of the lung may include surgery, radiation therapy, chemotherapy, or a combination of the two. Each option has its own benefits and risks.
The extent of the disease, the type of cancer, and the patient’s tolerance for medication will influence the type of surgery and treatment that is recommended. In addition, the tumor’s location, whether it is resectable, and the patient’s health are all factors in the decision to undergo surgery.
If surgery is chosen, the surgeon will first determine whether the tumor is resectable. For some tumors, however, a portion of the lung or the entire lung will need to be removed. The doctor will also evaluate the patient’s lung and heart health. This is because a patient with lung or heart disease may not be able to have a resection.
The doctor will then recommend a treatment plan that is best for the patient. Some patients may benefit from chemotherapy before and after surgery. These drugs are designed to destroy rapidly growing cancer cells. Some chemotherapy drugs are given intravenously while others are given through a catheter.
Other treatments include immunotherapy, which uses the immune system to fight cancer. This method of treatment is used in some non-small cell lung cancers. It interferes with the way the cancer cells hide from the immune system. In addition, cancer may be treated with targeted therapy, which targets specific parts of cancer.
These treatments can help relieve the symptoms of lung cancer. They can also prevent cancer from spreading. The goal of these types of treatments is to lengthen the patient’s life. In some cases, they can even make cancer disappear.
Getting the right diagnosis for squamous cell carcinoma of the lung is essential. The type of tumor, its size, its location, and the stage of cancer all affect the treatment. The patient’s age, general health, and overall response to the treatment also contribute to the prognosis.
Squamous cell carcinoma starts in the cells that line the surface of the air passages in the lungs. This cancer can spread to other parts of the body.
In addition to a biopsy, doctors use a CT scan and X-rays to determine whether the tumor is cancerous. Other tests may include MRI, positron emission tomography, and bone scans. A complete blood count can help to determine the type of cancer.
Surgery is sometimes needed to remove the tumor. In certain cases, radiation therapy and chemotherapy are combined with surgery. The treatment team will work with the patient to find the best course of action.
Lung cancer is usually diagnosed when a patient has a symptom. This can be a lump in the chest, a pulmonary mass, or atelectasis (a swelling that causes pain or pressure). The pleura is a thin layer of tissue that lines the outside of the lungs. Normally, it contains a small amount of fluid that helps the lungs move smoothly in the chest when breathing.
When the tumor has spread, it is called metastatic cancer. It may have spread to the lymph nodes in the chest and may have spread to other parts of the body. The treatment is also different for people with metastasized cancer. This type of cancer usually has a poor prognosis. The patient’s response to the treatment and the size of the tumor are also factors in the prognosis.
Using chemotherapy for squamous cell carcinoma of the lung depends on a number of factors. These include the type of lung cancer and the patient’s overall health. If cancer is diagnosed, the treatment team will work together with the patient to determine the best course of action.
A medical oncologist will decide whether chemotherapy is needed. If the cancer is not responsive to radiation or surgery, the patient may be given chemotherapy to prevent the disease from spreading. Some patients with squamous cell lung cancer are also offered immunotherapy. This treatment focuses on using drugs to attack cancer cells and cause less damage to healthy cells.
In addition to chemotherapy, the medical oncologist will prescribe drugs to alleviate the symptoms. Side effects can include nausea, vomiting, diarrhea, and low blood cells. The chemotherapy schedule will also be set, usually over a specific period of time.
If cancer has spread to other parts of the body, treatment will depend on the patient’s overall health. Some doctors will also use tests to monitor the patient’s status. They may do CT scans, bronchoscopy, and other tests.
A tumor that has spread to the brain may be treated with radiation therapy. This is used to shrink the tumor and prevent it from growing. In addition, a second surgery may be necessary to make sure all of cancer has been removed.
If cancer has spread to other organs, such as the lymph nodes, treatment will also be determined based on the patient’s overall health. The treatment may be chemotherapy, radiation therapy, or both.
A squamous cell lung cancer patient may be able to live longer if the cancer is treated early. The Eastern Cooperative Oncology Group (ECOG) prognostic score is one tool doctors use to judge a patient’s prognosis.
Depending on the type and stage of squamous cell carcinoma of the lung, your doctor may recommend chemotherapy and radiation therapy. These treatments can help shrink tumors before surgery. They also can reduce the chances of cancer recurring. These methods can help relieve symptoms for some patients.
Before deciding on a treatment plan, you will need to undergo a variety of tests. These tests will determine the stage of your cancer and the extent of its spread. The tests use a computer or magnet to look for cancer cells and a magnetic resonance imaging (MRI) machine to create detailed pictures of your body. Those tests will also determine if you have a certain risk factor for the disease.
After surgery, radiation and chemotherapy can be used to kill cancer cells that have been left behind. These treatments are called adjuvant therapies. Some cancers can benefit from chemotherapy alone, but some may need both to kill cancer before it grows too large. The drugs may be given orally, intravenously, or through a catheter.
A chest imaging study, or CT scan, can be used to find out if you have lung cancer. An abnormal imaging study may indicate that the tumor has spread to other parts of your body. If cancer has spread to other parts of your body, you will need to follow up with more tests to make sure cancer has not returned.
If you have a tumor that is affecting your quality of life, you may be referred to a doctor who specializes in a lung cancer treatment program. The doctor will work with you to develop a personalized treatment plan.
EGFR activating gene mutations
EGFR-activating gene mutations are rare in Squamous Cell Carcinoma of the Lung (SCC). EGFR is a tyrosine kinase receptor involved in growth regulation. Some adenocarcinomas overexpress wild-type EGFR and may therefore harbor EGFR-activating gene mutations. However, the presence of EGFR gene mutations in SCC is not well established. This study aims to characterize the distribution of EGFR gene mutations in SCC and to identify the role of these mutations in the tumor biology of SCC.
To determine the presence of EGFR gene mutations, a panel of 108 cancer-derived cell lines was examined. Of these, five SCCs were dissected into 100 pieces. Each of the five tumors was examined for EGFR gene mutations. A subset of EGFR mutations was identified in three areas of each tumor. These areas were morphologically distinct and varied histologically.
The EGFR mutations were detected by PCR-SSCP analysis. A panel of RT-PCR primers were used for the PCR-SSCP analysis. The result of the RT-PCR was followed by direct sequencing. The EGFR mutations were found in 41 SCCHN, including 3-point mutations, two deletions, and one in-frame deletion. The EGFR mutations were identified as L858R, G719X, and T790M. These mutations accounted for 39.4%, 4.3%, 2.1%, and 5.3% of patients, respectively.
All the patients were current smokers. No significant difference was observed in the survival rates between the patients with EGFR Del 19 and L858R mutations. The overall frequency of EGFR mutations was 5-20%, depending on the population.
The EGFR gene is expressed in non-small cell lung cancer (NSCLC). It is not well characterized for SCC. Nevertheless, adenocarcinomas are the most common histologic subtype of NSCLC. EGFR mutations are present in both primary lesions and metastatic lesions. EGFR TKIs can be effective in SCC.
Health A to Z. (n.d.). HSE.ie. https://www2.hse.ie/az/
U.S. National Library of Medicine. (n.d.). https://www.ncbi.nlm.nih.gov/
Directory Health Topics. (n.d.). https://www.healthline.com/directory/topics
Health A-Z. (2022, April 26). Verywell Health. https://www.verywellhealth.com/health-a-z-4014770
Harvard Health. (2015, November 17). Health A to Z. https://www.health.harvard.edu/health-a-to-z
Health Conditions A-Z Sitemap. (n.d.). EverydayHealth.com. https://www.everydayhealth.com/conditions/